P16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma

被引:126
作者
Brown, VL
Harwood, CA
Crook, T
Cronin, JG
Kelsell, DP
Proby, CM
机构
[1] Univ London, St Bartholomews & Royal London Sch Med & Dent, Ctr Cutaneous Res 2, London E1 2AT, England
[2] Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, London, England
关键词
p16(INK4a); p14(ARF); tumor supressor genes; CDKN2A; cutaneous squamous cell carcinoma; gene hyper methylation;
D O I
10.1111/j.0022-202X.2004.22501.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The p16(INK4a) and p14(ARF) tumor suppressor genes (TSGs) are encoded within the CDKN2A locus on chromosome 9p21 and function as cell cycle regulatory proteins in the p53 and RB pathways. Inactivation of these genes by genetic and epigenetic changes has been described in some human cancers, but their importance in cutaneous squamous cell carcinoma (SCC) has not been established. Our detailed examination of 40 cutaneous SCC revealed loss of heterozygosity of 9p21 markers in 32.5% of cases. Mutational analysis confirmed five point mutations in four of 40 SCCs. These mutations changed the amino acid sequence of p16(INK4a) in four tumors and p14(ARF) in three tumors. Promoter methylation of p16(INK4a) and p14(ARF) was detected in 13 of 36 (36%) and 16 of 38 (42%) cases, respectively. Absent protein expression was confirmed by immunohistochemistry in 13 of 16 (82%) of the tumors with biallelic inactivating events. Overall, the frequency of 9p21 alterations was 76% and for both p16(INK4a) and p14(ARF), promoter methylation is the commonest mechanism of gene inactivation. Alterations at this locus were significantly more common in tumors from immunocompetent compared with immunosuppressed individuals. These data confirm the importance of inactivation of p16(INK4a) and p14(ARF) TSGs in the pathogenesis of cutaneous SCCs.
引用
收藏
页码:1284 / 1292
页数:9
相关论文
共 50 条
[1]   Primary care: Cutaneous squamous-cell carcinoma [J].
Alam, M ;
Ratner, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (13) :975-983
[2]   p14ARF links the tumour suppressors RB and p53 [J].
Bates, S ;
Phillips, AC ;
Clark, PA ;
Stott, F ;
Peters, G ;
Ludwig, RL ;
Vousden, KH .
NATURE, 1998, 395 (6698) :124-125
[3]   Prognostic significance of p16INK4a alterations and 9p21 loss of heterozigosity in locally advanced laryngeal squamous cell carcinoma [J].
Bazan, V ;
Zanna, I ;
Migliavacca, M ;
Sanz-Casla, MT ;
Maestro, ML ;
Corsale, S ;
Macaluso, M ;
Dardanoni, G ;
Restivo, S ;
Quintela, PL ;
Bernaldez, R ;
Salerno, S ;
Morello, V ;
Tomasino, RM ;
Gebbia, N ;
Russo, A .
JOURNAL OF CELLULAR PHYSIOLOGY, 2002, 192 (03) :286-293
[4]   An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele [J].
Bertram, CG ;
Gaut, RM ;
Barrett, JH ;
Pinney, E ;
Whitaker, L ;
Turner, F ;
Bataille, V ;
Silvaj, ID ;
Swerdlow, AJ ;
Bishop, DT ;
Bishop, JAN .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (04) :961-965
[5]   A ROLE FOR SUNLIGHT IN SKIN-CANCER - UV-INDUCED P53 MUTATIONS IN SQUAMOUS-CELL CARCINOMA [J].
BRASH, DE ;
RUDOLPH, JA ;
SIMON, JA ;
LIN, A ;
MCKENNA, GJ ;
BADEN, HP ;
HALPERIN, AJ ;
PONTEN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) :10124-10128
[6]  
Esteller M, 2001, CANCER RES, V61, P2816
[7]  
Esteller M, 2000, CANCER RES, V60, P129
[8]  
Esteller M, 2001, CANCER RES, V61, P3225
[9]   CDKN2a/p16INK4a mutations and lack of 0p19ARF involvement in familial melanoma kindreds [J].
Fargnoli, MC ;
Chimenti, S ;
Keller, G ;
Soyer, HP ;
Dal Pozzo, V ;
Höfler, H ;
Peris, K .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 111 (06) :1202-1206
[10]  
Gasco M, 2002, CANCER RES, V62, P2072